5 Nasdaq Penny Stocks to Watch on April 14

nasdaq penny stocks

When it comes to stock market exchanges, there are very few that match up to the Nasdaq. It is one of the world’s biggest stock exchanges, and a large number of penny stocks are also listed on it. Considering the status that the exchange enjoys, it could be worthwhile for investors to take a look at some of the promising Nasdaq penny stocks. This morning, the Dow Jones Industrial Average jumped by 400 points, which could also present an opportunity to investors who are looking to invest in Nasdaq penny stocks.

Over the years, penny stocks have proven to be a good option for many investors who hunt for value in the markets. Penny stocks often present an opportunity for an investor to make significant returns through relatively small investments. One of the best possible hunting grounds for such stocks could be the Nasdaq, and at a time when the markets are volatile, investors could consider tracking the penny stocks listed on the exchange.

On that note, here is a closer look at 5 Nasdaq penny stocks that could be tracked by investors right now:

>> 5 Safe-Haven Gold Penny Stocks to Buy This Week

 

5 Nasdaq Penny Stocks to Watch: New Age Beverages (NASDAQ:NBEV)

New Age Beverages announced its projections for its first fiscal quarter this morning, and the numbers created a lot of optimism around the stock. The company revealed that its revenue for the fiscal first quarter is going to be in the $62 million to $64 million range. That is higher than analyst estimates of $56.7 million. After the announcement, New Age stock soared by 29% in today’s trading session.

The gross margins for the quarter are expected to be in the low 60% to mid 60% range. In the year-ago period, the gross margins stood at 66%. After the rally this morning, it is likely that NBEV stock is going to be in focus.

5 Nasdaq Penny Stocks to Watch: MEI Pharma (NASDAQ:MEIP)

nasdaq penny stocks

One Nasdaq penny stock that made significant gains this morning is MEI Pharma. This morning, the company announced that it had reached an agreement with Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) to develop and market a medicine meant for the treatment of B-cell blood cancers. The medicine in question is ME-401.

>> 5 Penny Stock Gainers to Watch

By way of this deal, MEI will be paid $100 million straight away, and in addition to that, the company stands to earn as much as $581 million in milestone payments. The news resulted in a strong rally in the stock this morning, which soared by 50% to $2.51.

5 Nasdaq Penny Stocks to Watch: Nantkwest Inc (NASDAQ:NK)

Investors looking for a play from among Nasdaq penny stocks could also consider having a closer look at NantKwest stock. This morning, the stock soared by 17% after it emerged that, along with ImmunityBio, NantKwest is engaged in talks with the United States Food and Drug Administration regarding a pair of products.

The products in question are potential therapeutics and vaccines meant for coronavirus patients. The rally in NK stock has put NantKwest stock in sharp focus, and investors could do well to keep an eye on it.

5 Nasdaq Penny Stocks to Watch: Aldeyra Therapeutics Inc (NASDAQ:ALDX)nasdaq penny stocks

ALDX stock has emerged as another intriguing option for investors on the hunt for promising Nasdaq penny stocks. This morning, Aldeyra announced encouraging top-line data from the phase 1 clinical trial of its systemic immune-mediated diseases product, ADX 629.

Additionally, the company also stated that it intends to have a Phase 2 clinical trial of the product soon. After the announcement, the stock soared by 17%.

>> Read More Penny Stock News

Featured image: DepositPhotos © Rangizzz

Please See Disclaimer


Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of Microsmallcap.com or its officers. The author is wholly responsible for the validity of all statements. Microsmallcap.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Microsmallcap.com to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Microsmallcap.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Microsmallcap.com does not render general or specific investment advice. Any information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Microsmallcap.com does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.